Premium
Dietary lipids modulate the expression of miR‐107, a miRNA that regulates the circadian system
Author(s) -
DaimielRuiz Lidia,
KlettMingo Mercedes,
Konstantinidou Valentini,
Micó Victor,
Aranda Juan Francisco,
García Belén,
MartínezBotas Javier,
Dávalos Alberto,
FernándezHernando Carlos,
Ordovás José Maria
Publication year - 2015
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.201570094
Subject(s) - circadian rhythm , microrna , biology , gene , transcription factor , gene expression , regulation of gene expression , endocrinology , microbiology and biotechnology , medicine , genetics
Scope The increased prevalence of cardiovascular diseases (CVDs) has been hypothesized to be the result of an increased exposure to a host of atherogenic environmental factors, paramount among them being unhealthy dietary habits. Long‐chain n‐3 polyunsaturated fatty acids (PUFAs) have been shown to have cardio protective effects, partially due to their ability to regulate gene expression. In this regard, increasing attention has been devoted to the role of miRNAs as regulators of multiple metabolic pathways whose deregulation has been associated with CVD risk. In this work we investigated whether miRNA expression was regulated by docosahexanoic acid, conjugated linoleic acid and cholesterol in Caco‐2 cells. Results Among the modulated miRNAs, miR‐107 was differentially expressed by all treatments and this modulation was independent of its hosting gene, panthothenate kinase 1, possibly through its own promoter, which contains binding sites for metabolically relevant transcription factors. Among the putative target genes of miR‐107, we found some genes with key roles in circadian rhythm. Specifically, we demonstrated that binding of miR‐107 to the circadian locomotor output cycles kaput gene results in the deregulation of the circadian rhythm of the cells. Conclusion Since chronodisruption has been linked to metabolic disorders such as type 2 diabetes, atherosclerosis, obesity, and CVD, our findings suggest that miR‐107 could represent a new approach for pharmacological treatment of these diseases.